Peru Decentralized HIV Care
ConditionHIV
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorYale University
About this trial
The purpose of this study is to understand the processes by which HIV care is decentralized, an evidence-informed strategy to improve retention in HIV care, in Peru. Decentralization of HIV services has not been evaluated using experimental designs and urban decentralization studies of HIV are uncommon, so this study will lend important insights for future decentralization efforts in Peru and other countries.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Currently employed at a PHC or SHC that is participating in the study. Provide consent for participation.
Currently employed as a nurse or physician who fulfilled the ECHO training requirements
Currently serving as the leader of a PHC.
Disqualifiers
None
Trial design
Design model
Sequential
Treatments tested in this trial
NIATx + ECHO
BehavioralProject ECHO will be combined with NIATx to provide clinical skills to PHC staff and delivered in a hub and spoke model to connect SHC and PHC staff in delivery of HIV care. Decentralization will occur through guideline concordance, facilitated through NIATx and ECHO.
Treatment groups
1,450 Participants
are divided into 3 treatment groupsGroup A: Group 1Experimental treatment 1 intervention
Group B: Group 2Experimental treatment 1 intervention
Group C: Group 3Experimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Percentage of diagnosed PWH in treatment in PHC within the district
The percentage of diagnosed PWH in treatment in PHC within the district will be used to assess the extent to which decentralized services are adopted and scaled-up in PHCs. Higher percentage indicates more services adopted and scaled-up.
Time frame
up to month 54Secondary outcomes
1
Effectiveness assessed as the extent of RIC and VS within the district
The extent to which PWH are transferred from SHCs to PHCs and consequently are RIC and achieve VS assessed by the number of participants that are RIC and achieve VS
Time frame
up to month 54Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Yale University
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator
Source ClinicalTrials.gov